Quartesian and Ilikos Form Strategic Partnership

Quartesian and Ilikos have formed a partnership aimed at establishing and executing a business development strategy bringing Quartesian’s clinical data management, biometrics and pharmacovigilance solutions to European companies, and supporting Ilikos’ efforts to establish and promote clinical research platforms in new regions.
 
“Expanding our business in Europe has been a goal for Quartesian since our formation 17 years ago. A strategic partnership with Ilikos will enable us to grow significantly in the European market. We are also excited about supporting Ilikos in promoting clinical research in the META regions. This is all part of our plan to offer our cost effective and efficient clinical data services to a global market and contribute to the expansion of clinical research around the world,” said Benjamin Jackson, co-founder and chief executive officer, Quartesian.
 
Ilikos offers highly adaptive and tailored drug development solutions, from translational through proof of concept studies, to life science companies and CROs worldwide.

Elias Sayias, founder and chief executive officer, Ilikos, said, “This unique partnership represents Quartesian’s formal entry into our qualified provider network, a significant milestone in our efforts to develop clinical research platforms and research study opportunities within Cyprus and the META regions.”